Related references
Note: Only part of the references are listed.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Jae H. Park et al.
CLINICAL INFECTIOUS DISEASES (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Kenneth Cornetta et al.
MOLECULAR THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
Jeremy S. Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Matthew Torre et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience
Kenneth Cornetta et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Amrom E. Obstfeld et al.
BLOOD (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
Conrad Russell Cruz et al.
CYTOTHERAPY (2010)
Vasopressin versus norepinephrine infusion in patients with septic shock
James A. Russell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)